These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 26359046)

  • 1. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000.
    Fischer B; Murphy Y; Rudzinski K; MacPherson D
    Int J Drug Policy; 2016 Jan; 27():23-35. PubMed ID: 26359046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review.
    Fischer B; Argento E
    Pain Physician; 2012 Jul; 15(3 Suppl):ES191-203. PubMed ID: 22786457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010.
    Murphy Y; Goldner EM; Fischer B
    Pain Physician; 2015; 18(4):E605-14. PubMed ID: 26218951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of cannabis in response to the opioid crisis: A review of the literature.
    Vyas MB; LeBaron VT; Gilson AM
    Nurs Outlook; 2018; 66(1):56-65. PubMed ID: 28993073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extent of illicit drug use and dependence, and their contribution to the global burden of disease.
    Degenhardt L; Hall W
    Lancet; 2012 Jan; 379(9810):55-70. PubMed ID: 22225671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Displacement of Canada's largest public illicit drug market in response to a police crackdown.
    Wood E; Spittal PM; Small W; Kerr T; Li K; Hogg RS; Tyndall MW; Montaner JS; Schechter MT
    CMAJ; 2004 May; 170(10):1551-6. PubMed ID: 15136548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN).
    Fischer B; Cruz MF; Rehm J
    Can J Psychiatry; 2006 Sep; 51(10):624-34. PubMed ID: 17052030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of illegal opioid use and health services utilization in Canada.
    Popova S; Rehm J; Fischer B
    Public Health; 2006 Apr; 120(4):320-8. PubMed ID: 16476455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada.
    Johnson S; MacDonald SF; Cheverie M; Myrick C; Fischer B
    Drug Alcohol Depend; 2012 Jul; 124(1-2):172-6. PubMed ID: 22265193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications.
    Firestone M; Goldman B; Fischer B
    Int J Drug Policy; 2009 Jan; 20(1):90-2. PubMed ID: 18508256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice.
    Lucas P
    Int J Drug Policy; 2009 Jul; 20(4):296-303. PubMed ID: 19124233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later.
    Fischer B; Gooch J; Goldman B; Kurdyak P; Rehm J
    Can J Public Health; 2014 Apr; 105(2):e146-9. PubMed ID: 24886852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.
    Murphy Y; Wilson E; Goldner EM; Fischer B
    Clin Drug Investig; 2016 Jul; 36(7):519-30. PubMed ID: 27056579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription opioid use and non-fatal overdose in a cohort of injection drug users.
    Lake S; Wood E; Buxton J; Dong H; Montaner J; Kerr T
    Am J Drug Alcohol Abuse; 2015 May; 41(3):257-63. PubMed ID: 25699628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opioid crisis in Canada: a national perspective.
    Belzak L; Halverson J
    Health Promot Chronic Dis Prev Can; 2018 Jun; 38(6):224-233. PubMed ID: 29911818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks.
    Hyshka E; Anderson-Baron J; Karekezi K; Belle-Isle L; Elliott R; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Hathaway A; Wild TC
    Harm Reduct J; 2017 Jul; 14(1):50. PubMed ID: 28747183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.
    Ansari B; Tote KM; Rosenberg ES; Martin EG
    Public Health Rep; 2020; 135(1_suppl):100S-127S. PubMed ID: 32735190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015.
    Wild TC; Pauly B; Belle-Isle L; Cavalieri W; Elliott R; Strike C; Tupper K; Hathaway A; Dell C; MacPherson D; Sinclair C; Karekezi K; Tan B; Hyshka E
    Int J Drug Policy; 2017 Jul; 45():9-17. PubMed ID: 28454045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.
    Mounteney J; Giraudon I; Denissov G; Griffiths P
    Int J Drug Policy; 2015 Jul; 26(7):626-31. PubMed ID: 25976511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Marijuana programs: implications for cannabis control policy--observations from Canada.
    Fischer B; Kuganesan S; Room R
    Int J Drug Policy; 2015 Jan; 26(1):15-9. PubMed ID: 25287942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.